Turnstone biologics corp. reports positive initial data from phase 1 trial of tidal-01 in metastatic colorectal cancer

Overall response rate (“orr”) of 25% and 50% disease control rate ("dcr") observed in first four evaluable patients treated with tidal-01 with advanced crc complete response achieved in heavily pre-treated late line patient with progression free survival extending beyond one year favorable tolerability profile and demonstrated manufacturing success product characterization and translational data support biological hypothesis for selected tils san diego, aug. 14, 2024 (globe newswire) -- turnstone biologics corp. (“turnstone” or the “company”) (nasdaq: tsbx), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (selected til) therapy, today reported positive initial data from its phase 1 starling trial of tidal-01 in metastatic microsatellite stable colorectal cancer (“mss mcrc”). turnstone's phase 1 starling trial is an ongoing muti-site, first-in-human, non-randomized, open label, single-dose study, and is evaluating the safety, tolerability, and clinical activity of tidal-01.
TSBX Ratings Summary
TSBX Quant Ranking